[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"survival-analysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:survival-analysis":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100619696","lidocaine-decreases-postoperative-lung-cancer-reoccurance-and-metatasis-risk-100619696",false,"NCT07347977","Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk","Lidocaine Infusion Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk: a Multicenter Randomized Controlled Study","LidCRM","Inclusion Criteria:\n\n1. Age range: 18-80 years old.\n2. Electively undergo minimally invasive (thoracoscopic or robotic) surgery for the treatment of lung cancer\n3. Is willing and capable of providing consent.\n\nExclusion Criteria:\n\n1. Palliative surgery without intention of cure.\n2. Extensive comorbidities (ASA IV).\n3. Patients with known or suspected allergy to lidocaine.\n4. Patients who are currently pregnant or breastfeeding.\n5. Patients who may experience adverse reactions due to accumulation of lidocaine during intravenous infusion, as stated in the Summary of Product Characteristics (SmPC) for lidocaine.\n6. Currently, there is abnormal liver function, with ALT or AST levels exceeding the laboratory reference range by a factor of 2.\n7. Currently, there is severe renal insufficiency (serum creatinine ≥451umol\u002FL or glomerular filtration rate (calculated using the MDRD formula) \\\u003C30ml\u002Fmin).\n8. Epilepsy.\n9. Patients with cardiac conduction abnormalities, including second-degree or third-degree heart block without a pacemaker, left bundle branch block, sick sinus syndrome, and pre-excitation syndrome (confirmed by medical history and electrocardiogram), as well as those with low cardiac output due to reduced left ventricular ejection fraction.\n10. Concurrent use with continuous infusion of other local anesthetic drugs (such as epidural).\n11. Patients who use drugs that may cause reasons for exclusion, including Class I and Class III antiarrhythmic drugs (such as mexiletine and amiodarone), cimetidine, and antiviral drugs. Eligibility will be determined by local clinicians and verified by clinical trial doctors.\n12. Patients with body weight \\\u003C40kg","ALL","18 Years","80 Years",{"count":21,"type":22},1400,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to explore if perioperative lidocaine infusion decreases disease reoccurrence and metastasis risk in non-small cell lung cancer patients.\n\nParticipants will be randomly assigned (1:1) to the lidocaine or placebo group. The intervention initiates within 30 minutes before anesthesia induction with an intravenous loading dose of 1.5 mg\u002Fkg administered over 10-20 minutes. This is followed by a continuous maintenance infusion of 1.5-3 mg\u002Fkg\u002Fh (calculated as 1-1.5 mg\u002Fkg\u002Fh in protocol text, see note below) during surgery, terminating 1 hour after skin closure. Participants will be followed up for 36 months post-surgery. Blood samples will be collected at baseline, postoperative day 1, day 3, and upon discharge",[28,29,30],"Non-Small Cell Lung Cancer","Recurrence","Survival Analysis",[32,33,29,34],"Lidocaine","Non-small cell lung cancer","Survival analysis","NOT_YET_RECRUITING","2026-01-11",{"date":38,"type":39},"2026-01-16","ACTUAL",{"date":41,"type":22},"2026-01-01",{"date":43,"type":22},"2029-12-30",{"name":45,"class":46},"First Affiliated Hospital of Ningbo University","NETWORK",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100606167","the-impact-of-transjugular-intrahepatic-portosystemic-shunt-on-recompensation-in-patients-with-decompensated-liver-cirrhosis-100606167","NCT07172035","The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis","Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Recompensation in Patients With Decompensated Cirrhosis: A Multicenter Prospective Cohort Study","Inclusion Criteria:\n\n1. Age between 18 and 80 years old;\n2. Diagnosed with decompensated liver cirrhosis (diagnostic criteria: positive liver histopathological examination, or comprehensive judgment based on clinical symptoms, biochemical indicators and imaging features);\n3. The etiology of liver cirrhosis is intervenable (including hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, alcoholic liver disease (ALD), etc.);\n4. Patients with indications for Transjugular Intrahepatic Portosystemic Shunt (TIPS) treatment of cirrhotic portal hypertension, such as those with cirrhotic portal hypertension-related esophagogastric variceal bleeding refractory to endoscopic treatment, and patients with refractory ascites caused by cirrhotic portal hypertension;\n5. Obtained informed consent signed by the patient or their family members.\n\nExclusion Criteria:\n\n1. Compensated liver cirrhosis at the time of TIPS treatment (without decompensated events such as ascites, hepatic encephalopathy, or esophagogastric variceal bleeding);\n2. TIPS performed for the treatment of non-cirrhotic portal hypertension (e.g., idiopathic portal hypertension, Budd-Chiari syndrome, sinusoidal obstruction syndrome, etc.);\n3. Patients complicated with malignant tumors such as hepatocellular carcinoma (HCC), renal cell carcinoma, or lung cancer prior to TIPS;\n4. Patients with severe cardiopulmonary dysfunction or a Model for End-Stage Liver Disease (MELD) score \\> 18;\n5. Pregnant patients;\n6. Patients with uncontrolled systemic infection or inflammation;\n7. Patients with severe coagulation disorders;\n8. Patients allergic to contrast medium.\n\nCriteria for Termination\u002FWithdrawal from the Study:\n\n1. Patients with Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure failure due to various reasons;\n2. Patients who voluntarily request to withdraw from the study.",{"count":56,"type":22},250,"OBSERVATIONAL","The traditional view holds that the natural course of cirrhosis is a unidirectional process, characterized by irreversible progression from the compensated stage to the decompensated stage, and is highly likely to develop further decompensation events or even death. However, a growing body of evidence suggests that the natural course of cirrhosis is not always unidirectional - after the removal of the etiology, the structural and functional changes of the liver may be partially reversed. This understanding has given rise to the concept of \"liver recompensation,\" which has been standardized at the Baveno VII Consensus Conference. Notably, in a cohort of patients with alcohol-related cirrhosis, 18% achieved recompensation, which was significantly associated with a reduction of more than 90% in liver-related mortality. In patients with hepatitis B-related cirrhosis, 6% achieved recompensation after treatment with nucleos(t)ide analogs, with a similar improvement in mortality.\n\nTransjugular intrahepatic portosystemic shunt (TIPS) is a well-established therapy for complications related to portal hypertension, including gastroesophageal variceal bleeding, refractory ascites, and hepatic hydrothorax. Compared with standard treatment, TIPS has been proven to reduce the incidence of further decompensation and improve transplant-free survival. However, due to portal blood shunting, the risks of abnormal liver function and hepatic encephalopathy (HE) also increase. It is worth noting that TIPS is not included in the definition of recompensation in the Baveno VII Consensus. Therefore, whether patients with cirrhosis who undergo TIPS treatment can achieve recompensation and which factors determine the probability of recompensation remain unknown. More importantly, the impact of recompensation on the risk of HCC development and mortality in TIPS patients has not been studied prospectively.",[60,61,62,30],"Cirrhosis","Decompensation","Transjugular Intrahepatic Portosystemic Shunt (TIPS)",[60,64,65,34],"decompensation","transjugular intrahepatic portosystemic shunt (TIPS)","RECRUITING","2025-11-27",{"date":69,"type":39},"2025-12-05",{"date":71,"type":39},"2025-08-01",{"date":73,"type":22},"2027-08-01",{"name":75,"class":76},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",15,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":88,"conditions":89,"keywords":99,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100551962","evaluation-of-intra-operative-photographs-for-the-assessment-of-a-proper-lymphadenectomy-in-minimally-invasive-gastrectomies-for-gastric-cancer-photonodes-100551962","NCT06466902","Evaluation of Intra-operative Photographs for the Assessment of a Proper Lymphadenectomy in Minimally-invasive Gastrectomies for Gastric Cancer (PhotoNodes)","Evaluation of Intra-operative Photographs for the Assessment of a Proper Lymphadenectomy in Minimally-invasive Gastric Cancer Surgery (PhotoNodes)","PhotoNodes","Inclusion Criteria:\n\n* All patients undergoing minimally invasive curative-intent surgery for gastric adenocarcinoma with D2 lymphadenectomy\n* Patients undergoing upfront surgery or treated with a neoadjuvant\u002Fperioperative chemotherapy\n* Total or Subtotal Gastrectomy\n* Laparoscopic or Robotic approach\n\nExclusion Criteria:\n\n* Age less than 18 year old\n* Esophago-gastric junction cancer Siewert type I, II or III\n* Metastatic disease\n* Lymphadenectomy less than D2\n* Open surgery\n* Conversion to open surgery\n* Palliative gastrectomy\n* R1 or R2 resection\n* Multivisceral resection except for cholecystectomy\n* Surgical procedures other than subtotal or total gastrectomy\n* A single node station rated as unevaluable by more than one reviewer",{"count":87,"type":22},326,"Even after the wide introduction of chemo\u002Fradiotherapy in the treatment algorithm, adequate surgery remains the cornerstone of gastric cancer treatment with curative intent. A proper D2 lymphadenectomy is associated with improved cancer specific survival as confirmed in Western countries by fifteen-year follow-up results of Dutch and Italian randomized trials.\n\nIn clinical practice, the total number of harvested lymph nodes is often considered as a surrogate marker for adequate D2 lymphadenectomy; nonetheless, the number of retrieved nodes does not necessarily correlate with residual nodes, which intuitively could represent a more reliable marker of surgical adequacy. The availability of an efficient tool for evaluating the absence of residual nodes in the operative field at the end of node dissection could better correlate with survival outcomes.\n\nThe goal of this multicentric observational prospective study is to test the reliability of a new score (PhotoNodes Score) created to rate the quality of the lymphadenectomy performed during minimally invasive gastrectomy for gastric cancer. The score is assigned by assessing the absence of residual nodes at the end of node dissection on a set of laparoscopic\u002Frobotic high quality intraoperative images collected from each patient undergoing a minimally invasive gastrectomy with D2 node dissection.\n\nIdeally, this tool could be a new indicator of the quality of D2 dissection and could assume a prognostic role in the treatment of gastric cancer.",[90,91,92,93,94,95,96,97,30,98],"Gastric Cancer","Gastric Adenocarcinoma","Lymphadenectomy","Minimally Invasive Surgery","Gastrectomy for Gastric Cancer","Laparoscopic Surgery","Robotic Surgery","Survival Outcomes","Quality Of Care",[100,101],"D2 Lymphadenectomy quality assessment","Minimally invasive gastric cancer oncologic surgery","2024-07-03",{"date":104,"type":39},"2024-07-05",{"date":106,"type":39},"2022-12-22",{"date":108,"type":22},"2027-12",{"name":110,"class":76},"Azienda Ospedaliero-Universitaria di Parma",8]